First-in-class ADCs tailor designed to attack advanced cancer.
Company Focus
Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.
Advanced cancer requires advanced solutions.
90% of advanced cancer patients are likely to become refractory and left with no viable treatment options
Our Vision
Advanced cancer patients often endure multiple lines of treatment and are frequently left with no remaining options. A critical challenge lies in the limited understanding of how cancer changes across treatment lines, complicating the identification of novel targets that hold substantial therapeutic potential.
Ona aspires to bring forward new therapeutics with unprecedented efficacies through a pointed understanding of refractory cancer biology and its plasticity. By incorporating real-world samples from refractory patients, we are identifying how standard of care changes cancer at the molecular level. This strategy enables Ona to source targets beyond traditional tumor antigens and define new patient populations where our therapeutics will be highly efficacious.
Process & Approach
Ona’s process is rooted in the skillful pairing of target disease biology with therapeutic antibody mechanisms – with a primary focus on creating precision ADCs.
1
Biology Expertise
Identifying therapeutic targets is crucial for success. We strategically identify novel targets directly from privileged clinical research partnerships.
2
Efficient Development
Executing a streamlined development process ensures resources are allocated and utilized to only progress highly active and tolerable candidates.
3
Precision Targeting
We position our ADCs for success through profiling target expression in healthy and cancerous tissues derived from the patient cohorts we intend to treat.
4
Antibody Customization
We fine tune our ADCs and antibodies with cutting edge engineering techniques, ensuring a maximum therapeutic benefit through optimized pharmacokinetics and prolonged tolerability.
Pipeline
Name |
Target |
Indication |
Discovery |
Pre-clinical |
IND-enabling |
Clinical |
|---|---|---|---|---|---|---|
ONA-255ADC |
undisclosed |
HR+ HER2- Breast Cancer |
||||
ONA-388ADC |
undisclosed |
Prevalent solidtumors |
||||
ONA-036mAB |
CD36 |
Acute Myeloid Leukemia |
||||
Leadership
Since its founding Ona Therapeutics has been managed by a highly experienced multinational team of biotech executives.
Advisors
Board of Directors
About us
Founded in 2019, Ona Therapeutics is a biotechnology company spun out of ICREA and IRB, specializing in unravelling novel biology to design biotherapeutics for advanced cancers. Following the assembly of a multinational team of experienced biotech executives, Ona Therapeutics has maintained its focus on two wholly owned internal programs. Our lead program is an undisclosed first-in-class antibody drug conjugate that is being initially developed for a specific population of refractory breast cancer patients. We are also developing a monoclonal antibody against CD36, a metabolic regulator of fatty acid transport that has been implicated in multiple aspects of cancer progression.
Connect with Us
You can also write us at info@ona-therapeutics.com
and we will reply to you.
